Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Mark R. Wieland"'
Autor:
Shrirang V. Ranade, Mark R. Wieland, Tammy Tam, Jennifer C. Rea, Judit Horvath, Aaron R. Hieb, Weitao Jia, Lori Grace, Giulio Barteselli, Jay M. Stewart
Publikováno v:
Drug Delivery, Vol 29, Iss 1, Pp 1326-1334 (2022)
The Port Delivery System with ranibizumab (PDS) is an innovative intraocular drug delivery system designed for the continuous delivery of ranibizumab into the vitreous for 6 months and beyond. The PDS includes an ocular implant, a customized formulat
Externí odkaz:
https://doaj.org/article/28e8950e7cf747c48df86516bf005aaa
Autor:
Rahul N. Khurana, Louis K. Chang, Alok S. Bansal, James D. Palmer, Chengqing Wu, Mark R. Wieland
Publikováno v:
International Journal of Retina and Vitreous, Vol 5, Iss 1, Pp 1-7 (2019)
Abstract Background To determine whether aflibercept (Eylea; Regeneron Pharmaceuticals, Inc., Tarrytown, NY) could continue to extend the macular edema free interval in patients on a treat and extend (TAE) with non-ischemic central retinal vein occlu
Externí odkaz:
https://doaj.org/article/dd48c4d78a46477fbf7d52d70f90c84c
Autor:
Clement K. Chan, Maziar Lalezary, Prema Abraham, Michael Elman, Wesley Thomas Beaulieu, Steven G. Lin, Rahul N. Khurana, Alok S. Bansal, Mark R. Wieland, James D. Palmer, Louis K. Chang, Brandon J. Lujan, Glenn Yiu
Publikováno v:
Ophthalmology Retina. 6:484-494
Autor:
Dante J. Pieramici, Mark R. Wieland, Jay M. Stewart, Robert T. Chang, Shamika A. Gune, Varun K. Malhotra, Giulio Barteselli, Carl C. Awh
Publikováno v:
Ophthalmic surgery, lasersimaging retina. 53(5)
OBJECTIVE: To describe the Port Delivery System with ranibizumab implant insertion procedure. METHODS: A surgical procedure based on the clinical trial program in patients with retinal diseases. RESULTS: An infusion line is placed in the infero-tempo
Autor:
Carl C. Awh, Giulio Barteselli, Sneha Makadia, Robert T. Chang, Jay M. Stewart, Mark R. Wieland, Raymond Brassard, Natalia F. Callaway, Shamika Gune, Pam Heatherton, Varun Malhotra, Jeffrey R. Willis, Dante J. Pieramici
Publikováno v:
Ophthalmology. Retina. 6(11)
To provide strategies for the management of key ocular adverse events (AEs) that may be encountered with the Port Delivery System with ranibizumab (PDS) in practice and provide recommendations that may mitigate such AEs based on clinical trial experi
Autor:
Mark R. Wieland, Chengqing Wu, James D. Palmer, Louis K. Chang, Alok S. Bansal, Rahul N. Khurana
Publikováno v:
International Journal of Retina and Vitreous, Vol 5, Iss 1, Pp 1-7 (2019)
International Journal of Retina and Vitreous
International Journal of Retina and Vitreous
Background To determine whether aflibercept (Eylea; Regeneron Pharmaceuticals, Inc., Tarrytown, NY) could continue to extend the macular edema free interval in patients on a treat and extend (TAE) with non-ischemic central retinal vein occlusions (CR
INCREASING SLEEP DURATION IS ASSOCIATED WITH GEOGRAPHIC ATROPHY AND AGE-RELATED MACULAR DEGENERATION
Autor:
James D. Palmer, Edwin E. Boldrey, Rahul N. Khurana, David M. Claman, Travis C. Porco, Mark R. Wieland
Publikováno v:
Retina. 36:255-258
Purpose Sleeping too much or too little has been associated with adverse health outcomes including total mortality, cardiovascular disease, Type 2 diabetes, and hypertension. This study explored the relationship between sleep patterns and age-related
Autor:
Alok S. Bansal, Sherri A. Van Everen, Pin-wen Wang, Lisa Tuomi, Mark R. Wieland, Rahul N. Khurana
Publikováno v:
Ophthalmology. 122(8):1573-1579
Purpose To investigate the influence of glycosylated hemoglobin (HbA1c) on treatment outcomes in patients with diabetic macular edema (DME) receiving intravitreal ranibizumab. Design Post hoc analysis of 2 identical phase III clinical trials assessin
Autor:
Chengqing Wu, James D. Palmer, Louis K. Chang, Alok S. Bansal, Rahul N. Khurana, Mark R. Wieland
Publikováno v:
Ophthalmology. Retina. 2(2)
Purpose To determine whether aflibercept (Eylea; Regeneron Pharmaceuticals, Tarrytown, NY) can extend the macular edema–free interval in patients with nonischemic central retinal vein occlusions (CRVOs) previously treated with ranibizumab (Lucentis
Autor:
Mark R. Wieland, Rahul N. Khurana
Publikováno v:
Ophthalmology Retina. 2:636-637